Dr. Jessica Bauman, MD
Claim this profileFox Chase Cancer Center
Studies Lung Cancer
Studies Solid Tumors
12 reported clinical trials
25 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
EGFR positive
2Solid Tumors
Stage IV
Stage III
ROS1 positive
Affiliated Hospitals
Clinical Trials Jessica Bauman, MD is currently running
EU101
for Solid Cancers
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Recruiting1 award Phase 1 & 210 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Jessica Bauman, MD
Clinical Trial Related4 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Jessica Bauman, MD has experience with
- Repotrectinib (TPX-0005)
- Carboplatin
- Cisplatin
- TAK-788
- Pemetrexed
- Seribantumab
Breakdown of trials Jessica Bauman, MD has run
Lung Cancer
Metastatic Tumor
Neck Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jessica Bauman, MD specialize in?
Jessica Bauman, MD focuses on Lung Cancer and Solid Tumors. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jessica Bauman, MD currently recruiting for clinical trials?
Yes, Jessica Bauman, MD is currently recruiting for 6 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Jessica Bauman, MD has studied deeply?
Yes, Jessica Bauman, MD has studied treatments such as Repotrectinib (TPX-0005), Carboplatin, Cisplatin.
What is the best way to schedule an appointment with Jessica Bauman, MD?
Apply for one of the trials that Jessica Bauman, MD is conducting.
What is the office address of Jessica Bauman, MD?
The office of Jessica Bauman, MD is located at: Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111-2497 United States. This is the address for their practice at the Fox Chase Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.